GSK $3.3 billion acquisition of Affinivax
We are advising GSK on the acquisition
Davis Polk is advising GSK plc on its acquisition of Affinivax, Inc. for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones. The transaction, which is expected to close in the third quarter of 2022, is subject to customary closing conditions, including the expiration or early termination of the waiting period under the Hart-Scott- Rodino Anti-Trust Improvements Act of 1976.
GSK is a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better and live longer. Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.
The Davis Polk corporate team includes partners William J. Chudd and Daniel Brass and associates Lisa Ogust and Ryan Olson. Partner David R. Bauer and associate David A. Frey are providing intellectual property advice. Partner Jennifer S. Conway and associate Kerri Thompson are providing executive compensation advice. Counsel Elina Khodorkovsky is providing tax advice. All members of the Davis Polk team are based in the New York office.